论文部分内容阅读
获得性血友病是一种罕见的出血性疾病,它是由非血友病患者自然地产生抗因子Ⅷ凝血活性(FⅧ:C)的抗体,而引起的一种血液中具有抗凝血活酶抗凝物质的出血性疾病。过去有很多名称,如假血友病、类血友病、免疫性血友病、获得性血友病及获得性因子Ⅷ抗凝物质素。在血友病甲中约有5％的患者可见特异性的抑制凝血活酶形成的抗凝物质,它的性质属于免疫抗体,是一种球蛋白,属于IgG型,其作用是促使因子Ⅷ灭能及阻碍凝血活酶的形成。通常在血友病患者治疗后7～10天发生,对输血治疗,特别是对输浓缩因子Ⅷ制剂有抗力,对输新鲜血、新鲜血浆或浓缩Ⅷ因子后无效时应怀疑本症。一、病因:循环血中出现因子Ⅷ抑制物大多发生于血友病甲病人经因子Ⅷ代替治疗后,其发生率一般估计约为5～10％,有的报
Acquired haemophilia is a rare hemorrhagic disease that is caused by naturally occurring anti-factor Ⅷ coagulation activity (F Ⅷ: C) antibodies in patients with non-haemophilia and results in a blood that has anticoagulant activity Hemorrhagic disease of enzyme anticoagulant substances. In the past there are many names, such as fake hemophilia, hemophilia, immune hemophilia, acquired hemophilia and acquired factor Ⅷ anticoagulant. In hemophilia A, about 5% of patients showed specific inhibition of thromboplastin formation of anticoagulant substances, its nature is immune antibody, is a globulin, is IgG type, its role is to promote factor VIII off Can hinder the formation of thromboplastin. Usually in hemophilia patients 7 to 10 days after treatment, the blood transfusion, in particular, is resistant to transfusion of factor VIII preparations, lose the new blood, fresh plasma or concentrated factor VIII should be suspicious of the disease. First, the etiology: circulating blood factor VIII inhibitors mostly occur in hemophilia A patients by factor Ⅷ instead of treatment, the incidence is generally estimated at about 5 to 10%, and some reported